| Nov 6 |
Viatris Q3 Earnings Preview: Focus on upcoming product launches and EBITDA growth
|
| Nov 5 |
What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?
|
| Nov 5 |
Viatris Announces Third Quarter 2024 Dividend
|
| Nov 4 |
Viatris to Report Q3 Earnings: What's in the Cards?
|
| Nov 4 |
Unveiling Viatris (VTRS) Q3 Outlook: Wall Street Estimates for Key Metrics
|
| Nov 2 |
These 10 Stocks Were S&P 500's Worst Performers In Biden's First Year: Could Trend Continue If Harris Wins 2024 Election?
|
| Oct 29 |
Viatris Named to Forbes' World's Top Companies for Women 2024 List
|
| Oct 29 |
Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference
|
| Oct 22 |
Viatris Ahead Of Q3 Earnings: No Longer A 'Screaming' Bargain, But Still A Buy
|
| Oct 17 |
Lexicon sells Viatris rights to cardio drug outside of the U.S. and Europe
|
